Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Raw Materials (2017 - 2024)

China Pharma Holdings filings provide 8 years of Raw Materials readings, the most recent being $869820.0 for Q3 2024.

  • On a quarterly basis, Raw Materials fell 53.69% to $869820.0 in Q3 2024 year-over-year; TTM through Sep 2024 was $869820.0, a 53.69% decrease, with the full-year FY2023 number at $1.8 million, up 0.52% from a year prior.
  • Raw Materials hit $869820.0 in Q3 2024 for China Pharma Holdings, down from $1.2 million in the prior quarter.
  • In the past five years, Raw Materials ranged from a high of $2.2 million in Q1 2023 to a low of $869820.0 in Q3 2024.
  • Median Raw Materials over the past 5 years was $1.8 million (2021), compared with a mean of $1.8 million.
  • Biggest five-year swings in Raw Materials: grew 20.5% in 2023 and later tumbled 53.69% in 2024.
  • China Pharma Holdings' Raw Materials stood at $2.1 million in 2020, then fell by 11.63% to $1.8 million in 2021, then changed by 0.0% to $1.8 million in 2022, then rose by 0.52% to $1.8 million in 2023, then crashed by 52.96% to $869820.0 in 2024.
  • The last three reported values for Raw Materials were $869820.0 (Q3 2024), $1.2 million (Q2 2024), and $1.7 million (Q1 2024) per Business Quant data.